CN101679235A - 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途 - Google Patents

氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途 Download PDF

Info

Publication number
CN101679235A
CN101679235A CN200880019555A CN200880019555A CN101679235A CN 101679235 A CN101679235 A CN 101679235A CN 200880019555 A CN200880019555 A CN 200880019555A CN 200880019555 A CN200880019555 A CN 200880019555A CN 101679235 A CN101679235 A CN 101679235A
Authority
CN
China
Prior art keywords
compound
prodrug
solvate
compounds
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880019555A
Other languages
English (en)
Chinese (zh)
Inventor
K·N·达克
S·K·耶普
S·E·斯凯拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of CN101679235A publication Critical patent/CN101679235A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880019555A 2007-05-10 2008-04-28 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途 Pending CN101679235A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91708107P 2007-05-10 2007-05-10
US60/917,081 2007-05-10
US1303007P 2007-12-12 2007-12-12
US61/013,030 2007-12-12
PCT/IB2008/001070 WO2008139287A1 (en) 2007-05-10 2008-04-28 Azetidine derivatives and their use as prostaglandin e2 antagonists

Publications (1)

Publication Number Publication Date
CN101679235A true CN101679235A (zh) 2010-03-24

Family

ID=39739736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880019555A Pending CN101679235A (zh) 2007-05-10 2008-04-28 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途

Country Status (27)

Country Link
US (1) US20080280877A1 (2)
EP (1) EP2155666A1 (2)
JP (1) JP2010526801A (2)
KR (1) KR20100009582A (2)
CN (1) CN101679235A (2)
AP (1) AP2009005047A0 (2)
AR (1) AR066524A1 (2)
AU (1) AU2008249744A1 (2)
BR (1) BRPI0811444A2 (2)
CA (1) CA2686517A1 (2)
CL (1) CL2008001305A1 (2)
CO (1) CO6260066A2 (2)
CR (1) CR11101A (2)
DO (1) DOP2009000256A (2)
EA (1) EA200901381A1 (2)
EC (1) ECSP099727A (2)
GT (1) GT200900293A (2)
IL (1) IL201874A0 (2)
MA (1) MA31366B1 (2)
MX (1) MX2009011998A (2)
PA (1) PA8779601A1 (2)
PE (1) PE20090282A1 (2)
SV (1) SV2009003407A (2)
TN (1) TN2009000470A1 (2)
TW (1) TW200904409A (2)
UY (1) UY31070A1 (2)
WO (1) WO2008139287A1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448965A (zh) * 2009-04-02 2012-05-09 阿勒根公司 前列腺素e受体拮抗剂
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256109A1 (en) * 2007-11-15 2010-10-07 Sarah Elizabeth Skerratt Azetidines As EP2 Antagonists
JP2012508225A (ja) * 2008-11-10 2012-04-05 ファイザー・リミテッド ピロリジン
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
AU2020388645B2 (en) * 2019-11-21 2026-03-19 University Of Utah Research Foundation TRPV4 receptor ligands
EP4359399A4 (en) * 2021-06-24 2025-04-23 Reservoir Neuroscience, Inc. EP2 antagonist compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8300860D0 (en) * 1983-01-13 1983-02-16 Shell Int Research Azetidine compounds
GB8415614D0 (en) * 1984-06-19 1984-07-25 Shell Int Research Azetidine derivatives
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
TW200300757A (en) 2001-11-16 2003-06-16 Schering Corp Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
SI1934174T1 (sl) * 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448965A (zh) * 2009-04-02 2012-05-09 阿勒根公司 前列腺素e受体拮抗剂
CN102448965B (zh) * 2009-04-02 2014-06-18 阿勒根公司 前列腺素e受体拮抗剂
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法

Also Published As

Publication number Publication date
PA8779601A1 (es) 2009-01-23
JP2010526801A (ja) 2010-08-05
TW200904409A (en) 2009-02-01
US20080280877A1 (en) 2008-11-13
WO2008139287A1 (en) 2008-11-20
BRPI0811444A2 (pt) 2014-10-29
CA2686517A1 (en) 2008-11-20
GT200900293A (es) 2010-05-17
DOP2009000256A (es) 2009-11-30
MA31366B1 (fr) 2010-05-03
IL201874A0 (en) 2010-06-16
EA200901381A1 (ru) 2010-06-30
TN2009000470A1 (fr) 2011-03-31
PE20090282A1 (es) 2009-03-27
CL2008001305A1 (es) 2008-07-18
SV2009003407A (es) 2010-01-12
CR11101A (es) 2009-12-04
UY31070A1 (es) 2009-01-05
ECSP099727A (es) 2009-12-28
MX2009011998A (es) 2009-11-19
AP2009005047A0 (en) 2009-12-31
AU2008249744A1 (en) 2008-11-20
AR066524A1 (es) 2009-08-26
KR20100009582A (ko) 2010-01-27
CO6260066A2 (es) 2011-03-22
EP2155666A1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
US11655223B2 (en) Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
CN101679235A (zh) 氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途
HK1225730A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
JP2015501833A (ja) スルホンアミド誘導体
TW201315727A (zh) 尿嘧啶衍生物及其醫藥用途
CN101107243A (zh) 作为催产素拮抗剂的取代三唑衍生物
US8278343B2 (en) Pyrrolidines
US20100256109A1 (en) Azetidines As EP2 Antagonists
HK1139661A (en) Azetidine derivatives and their use as prostaglandin e2 antagonists
HK1158197A (en) Pyrrolidines
HK40120007A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
CN119604287A (zh) 杂环pad4抑制剂
HK40042394A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
HK1255870B (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
HK1113927B (en) Substituted triazole derivatives as oxytocin antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139661

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100324

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139661

Country of ref document: HK